A protein that stem cells require could be a target in killing breast cancer cells – Medical Xpress
|
A protein that stem cells require could be a target in killing breast cancer cells
Medical Xpress When a stem cell differentiates, it starts down a one-way path that will result in its specialization and eventually its death. For instance, a stem cell in the breast can become a luminal cell, one of the breast’s “milk factories.” Such cells have a … |
Newsy |
China Is Set to Begin Its First Trials With Human Embryonic Stem Cells
Newsy In the next few months, doctors in China will start the country’s first clinical trials with human embryonic stem cells. They’re looking to treat Parkinson’s disease with brain cells called neural precursors, which come from stem cells in fertilized … |
ABC2 News |
China Is Set to Begin Its First Trials With Human Embryonic Stem Cells
ABC2 News In the next few months, doctors in China will start the country’s first clinical trials with human embryonic stem cells. They’re looking to treat Parkinson’s disease with brain cells called neural precursors, which come from stem cells in fertilized … |
Singularity Hub |
Limitless Lab-Grown Blood Is ‘Tantalizingly Close’ After 20 Years
Singularity Hub Blood stem cells are things of wonder: hidden inside each single cell is the power to reconstitute an entire blood system, like a sort of biological big bang. Yet with great power comes greater vulnerability. Once these “master cells” are compromised … |
Mesothelioma & Asbestos Awareness Center (blog) |
The Potential of Immunotherapy for Mesothelioma
Mesothelioma & Asbestos Awareness Center (blog) The immune system is often described as one of our greatest survival tools. It’s vital to fighting off dangers to our health, and an emerging treatment, immunotherapy, is harnessing its strength to better fight cancer. Immunotherapy is one of the most … Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors …PR Newswire (press release) A New Era of Cancer Research as ASCO Kicks Off24/7 Wall St. |
|
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 …
Nasdaq The phase 1b/2 immuno-oncology trial will evaluate Genentech’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens, and INO-9012, an immune activator encoding IL-12. BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 …Reuters |